Two of Egis’ fixed-dose combination drugs have won the Innovation Grand Prize. The awarded Egis medicines feature significant innovations as they reduce the risk of cardiovascular events related to atherosclerosis due to the combined lipid-lowering therapy. In respect of these two products the company obtained three patents related to active ingredient development and two patents related to formulation development that are all relevant to large-scale manufacturing technologies. The recognition was not without a history, as this is the tenth time an Egis medicine has received an Innovation Prize or Grand Prize.

Egis Pharmaceuticals PLC, celebrating the 110th anniversary of its foundation this year, is expanding its usual activities with new elements thanks to investments exceeding a total value of more than 100 billion HUF in Hungary over the past period.. Egis, one of the leading generic pharmaceutical companies in Eastern and Central Europe, now offers drug stubstance contract development and contract manufacturing services under the name of Egis Pharma Services to both existing and new pharmaceutical partners.

The Semmelweis University and Egis Pharmaceuticals PLC have agreed on an even closer cooperation than before. Our common goal is to further raise the standards of pharmaceutical R+D as well as pharmacist and doctor training by making use of the synergies in each other’s activities. As a result of the agreement, new health industrial innovations can be launched and the Semmelweis University can be extended with more practical educational and training elements that also meet the needs of the Hungarian pharmaceutical industry.

Egis and our consortia partners have won 2,332 billion HUF direct grant in the framework of the innovation tender GINOP-2.2.1-15-2016-00023 for the realisation of the above-mentioned project.